Comparison of 68Ga-FAPI-46 PET and 18F-FDG PET in Lung Cancer

Launched by CHANG GUNG MEMORIAL HOSPITAL · Nov 8, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging test called 68Ga-FAPI-46 to see how well it works in diagnosing lung cancer, especially in finding both the primary tumor and any spread of the disease to other parts of the body. Researchers will compare the results of this new test with a standard imaging test called 18F-FDG PET, which is already used for lung cancer detection. The trial is currently looking for participants, including adults over 20 years old who have been diagnosed with lung cancer or are suspected to have it based on their chest CT scans.

To participate, patients need to give their consent and be scheduled for an FDG-PET examination. They should not be pregnant or breastfeeding, and they should not have certain serious health conditions that could interfere with the study. Those who join the trial can expect to undergo both types of imaging tests as part of their lung cancer evaluation. This research aims to improve how we diagnose and understand lung cancer, ultimately helping patients receive better care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age \> 20 years
• • 2. Informed consent obtained from patients and families
• • 3. Patients with histology confirmed lung cancer or patients with GGO on chest CT planned to have biopsy or surgery
• • 4. Patients scheduled to undergo FDG-PET examination
• • 5. Performance status: 0, 1, 2, 3
• Exclusion Criteria:
• • 1. Contraindication to FAPI-PET and FDG-PET such as pregnant, or lactating patients
• • 2. Patients with mainly malignant pleural effusion without other measurable lesions
• • 3. Undergoing irradiation at accrual
• • 4. Active infection or other serious underlying medical conditions not compatible with study entry
• • 5. History of significant neurological or psychiatric disorders including dementia that would prohibit the understanding and giving of informed consent